• ASCO Presentations Highlight Clinical Utility of Caris Target Now™ in Molecular Profiling of Breast and Head and Neck Cancers

      – TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers –   –EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer – Chicago, Ill., June 2, 2012 – Caris Life Sciences, announced today the utility of the company’s Caris Target Now™ evidence-based molecular profiling service in the characterization of breast … Read More

  • Caris Target Now™ Data to be Showcased at ASCO 2012

    Evidence-Based Molecular Profiling Service to be Featured in Eight Separate Data Presentations   IRVING, TX, May 21, 2012 – Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced that eight data presentations on Caris Target Now™, the foremost evidence-based molecular profiling … Read More

  • Circulating Microvesicles Demonstrate Promise for Cancer Testing

    Three Posters on Novel Technology Presented at American Association for Cancer Research (AACR) IRVING, TX, April 4th, 2012 — Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, this weekend presented novel findings regarding the biological role of circulating microvesicles (cMV) in the … Read More

  • Novel Findings for Molecular Profiling of Head and Neck Squamous Cell Carcinoma (HNSCC) Presented at the 2012 Multidisciplinary Head & Neck Cancer Symposium

    First Comprehensive Analysis of Biomarkers Associated with this Aggressive Form of Cancer Demonstrates Clinical Utility of Molecular Profiling in Identifying Treatment Options When Therapeutic Ambiguities Exist. IRVING, TX, February 2, 2012 – Caris Life Sciences™, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality molecular profiling and blood-based … Read More

  • Caris Life Sciences and Miraca Holdings Complete Sale of Anatomic Pathology Business

    Tokyo, Japan & Irving, Texas – November 22, 2011 – Miraca Holdings Inc. (“Miraca”), Japan’s largest clinical diagnostics and laboratory testing service provider, and Caris Life Sciences, Inc. (“CLS”), a privately-held company headquartered in Texas specializing in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, today announced … Read More